By MANSUR SHAHEEN DEPUTY HEALTH EDITOR FOR DAILYMAIL.COM UPDATED: 12:16 EDT, 3 April 2023 America’s leading medical research agency is launching a largest-of-its-kind $300 million database with hopes of learning more about Alzheimer’s. The National Institute of Aging (NIA), an arm of the National Institutes of Health (NIH), hopes to launch the initiative as early as April...
by Ingrid Fadelli, Medical Xpress Representative 3D reconstructed image showing Homer1 engulfment within CD68+ lysosomes of P2Y12+ microglia. Credit: De Schepper et al Microglia are primary immune cells that safeguard the mammalian brain, partly by devouring or ‘phagocytosing’ pathogens and toxic debris. Recent genetic studies have consistently highlighted the role of microglia in the development of Alzheimer’s...
By Bronwyn Thompson March 21, 2023 Researchers have found the gene Surf4 plays a role in neural degeneration Depositphotos Nearly six million Americans currently live with Alzheimer’s disease (AD), with the figure set to climb to 13.8 million by 2050. And with promising trials failing close to the finish line, researchers are desperate for any breakthroughs that will lead...
by Drexel University PET scan of a human brain with Alzheimer’s disease. Credit: public domain Researchers from Drexel University have uncovered a novel regulatory mechanism in the brain that is essential for making the right kinds of proteins that promote healthy brain function, and its malfunctioning may be an early contributor of the development of Alzheimer’s...
by Brigham and Women’s Hospital Credit: Pixabay/CC0 Public Domain Preliminary results from a landmark clinical trial to prevent Alzheimer’s disease (AD) symptoms show that an investigational anti-amyloid drug, solanezumab, did not demonstrate a statistically significant slowing of cognitive decline associated with AD when initiated prior to the stage of clinical impairment. The Anti-Amyloid Treatment in...
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE Nearly two dozen experimental therapies targeting the immune system are in clinical trials for Alzheimer’s disease, a reflection of the growing recognition that immune processes play a key role in driving the brain damage that leads to confusion, memory loss and other debilitating symptoms. Many of the immunity-focused Alzheimer’s drugs...
by Public Library of Science Credit: Unsplash/CC0 Public Domain Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model, according to a new study publishing March 7 in the open access journal PLOS Biology by Rui Zhang of Air Force Medical...
UNIVERSITÄT LEIPZIG IMAGE: OXIDISED MODEL MEMBRANES HAVE DIFFERENT EFFECTS ON PEPTIDE FIBRIL FORMATION, DRIVEN BY MEMBRANE SURFACE ATTRACTION, PEPTIDE CHARGE AND PEPTIDE STRUCTURAL PROPERTIES. CREDIT: LEIPZIG UNIVERSITY The researchers wanted to better understand how cell membranes in the body influence the structure of peptides – these are molecules made up of amino acids – and their aggregation....
by Texas A&M University Dmitry Kurouski, Ph.D., standing, and research assistant Kiryl Zhaliazka, conducted a study linking cholesterol to Alzheimer’s disease. Credit: Department of Biochemistry and Biophysics Cholesterol tremendously increases the toxicity of a peptide implicated in Alzheimer’s progression, according to research by scientists in the Department of Biochemistry and Biophysics in Texas A&M’s College of Agriculture and Life...
by The Mount Sinai Hospital Credit: Pixabay/CC0 Public Domain Mount Sinai researchers have published a study in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association that sheds new light on the role of DNA methylation in Alzheimer’s disease (AD). The study found that DNA methylation has a profound impact on gene and protein co-expression networks associated with AD...
